KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Treasury Shares (2016 - 2025)

Gilead Sciences (GILD) has disclosed Treasury Shares for 17 consecutive years, with $17.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares fell 18.35% year-over-year to $17.8 million, compared with a TTM value of $17.8 million through Dec 2025, down 18.35%, and an annual FY2025 reading of $17.8 million, down 18.35% over the prior year.
  • Treasury Shares was $17.8 million for Q4 2025 at Gilead Sciences, down from $21.8 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $21.8 million in Q4 2024 and bottomed at $1.0 million in Q2 2021.
  • Average Treasury Shares over 5 years is $9.3 million, with a median of $7.0 million recorded in 2023.
  • The sharpest move saw Treasury Shares plummeted 70.0% in 2021, then skyrocketed 500.0% in 2022.
  • Year by year, Treasury Shares stood at $8.0 million in 2021, then soared by 137.5% to $19.0 million in 2022, then crashed by 31.58% to $13.0 million in 2023, then surged by 67.69% to $21.8 million in 2024, then decreased by 18.35% to $17.8 million in 2025.
  • Business Quant data shows Treasury Shares for GILD at $17.8 million in Q4 2025, $21.8 million in Q4 2024, and $11.0 million in Q3 2024.